Credit Suisse Group Trims AstraZeneca plc (LON:AZN) Target Price to GBX 4,700

AstraZeneca plc (LON:AZN) had its price objective trimmed by Credit Suisse Group from GBX 5,000 ($65.11) to GBX 4,700 ($61.21) in a report published on Friday, July 28th, Marketbeat Ratings reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

AZN has been the subject of several other reports. Liberum Capital reiterated a buy rating and set a GBX 5,100 ($66.41) target price on shares of AstraZeneca plc in a report on Thursday, April 27th. Barclays PLC restated an overweight rating and issued a GBX 6,000 ($78.14) price objective on shares of AstraZeneca plc in a report on Friday, April 28th. UBS AG set a GBX 5,150 ($67.07) price objective on shares of AstraZeneca plc and gave the stock a neutral rating in a report on Tuesday, June 27th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.79) target price on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Saturday, May 20th. Finally, HSBC Holdings plc set a GBX 4,500 ($58.60) target price on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Tuesday, June 6th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 4,932.67 ($64.24).

AstraZeneca plc (LON AZN) opened at 4448.50 on Friday. The firm’s market capitalization is GBX 56.32 billion. The company’s 50-day moving average price is GBX 4,999.51 and its 200-day moving average price is GBX 4,862.78. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00.

COPYRIGHT VIOLATION WARNING: “Credit Suisse Group Trims AstraZeneca plc (LON:AZN) Target Price to GBX 4,700” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://sportsperspectives.com/2017/08/10/credit-suisse-group-trims-astrazeneca-plc-lonazn-target-price-to-gbx-4700-updated.html.

The firm also recently announced a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.90) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.

In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($56.91) per share, for a total transaction of £1,704.30 ($2,219.43).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply